The overall objective of this program is to elucidate the molecular and genetic basis for abnormalities in lipoprotein metabolism that predispose to premature artery disease. The identification and characterization of such pathophysiological changes in humans will permit more rational management and better design of appropriate therapy in order to delay the onset of premature coronary artery disease. We will address this goal with four studies relating to abnormalities of high density lipoprotein (HDL). One project will focus on mapping of atherogenic traits, including LDL density, HDL level, and apolipoprotein B level in familial combined hyperlipidemia, the most common condition associated with premature therosclerosis. Mapping, followed by identification of previously undetected genes for these traits, will advance both the basic biology of lipid disorders and the potential to diagnose, prevent, and treat vascular disease. The other three projects will focus on proteins that are central to HDL metabolism: apolipoprotein (apo) A-L, phospholipids transfer protein (PLTP), and serum amyloid A (SAA). One part of the apo A-l project will focus on oxidative modifications that affect HDL's ability to remove cholesterol by the ABCA 1 pathway, a key early event in reverse cholesterol transport. Another part will identify the pathways for apo A-l reflect oxidative .in the artery wall and determine whether plasma levels of oxidized apo A-l reflect oxidative stress and inflammation. The PLTP project will uncover thebiochemical basis and functional differences of the different forms of PLTP and will identify the structural domains of PLTP and ABCA 1 that are critical for the interaction of PLTP with ABCA1 and for facilitation of lipid efflux from cells through this pathway. The study of serum amyloid A (SAA), which is carried on HDL, will explore the link between atherosclerosis and inflammation and SAA's role in HDL retention and atherosclerosis. By identifying genetic changes that lead to FCHL and alter HDL, studying proteins involved in reverse cholesterol transport (apo A-l and PLTP), and investigating the relationship between HDL and inflammation, this program project will take a multifaceted approach to elucidating the roles of HDL and related proteins in premature coronary artery disease.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Fleg, Jerome
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Zhang, Meng; Zhai, Xiaobo; Li, Jinping et al. (2018) Structural basis of the lipid transfer mechanism of phospholipid transfer protein (PLTP). Biochim Biophys Acta Mol Cell Biol Lipids 1863:1082-1094
Zhao, Xue-Qiao; Phan, Binh An P; Davis, Joseph et al. (2016) Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol 10:1091-7
Monette, Jeffrey S; Hutchins, Patrick M; Ronsein, Graziella E et al. (2016) Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration. Circ Res 119:83-90
Deguchi, Hiroshi; Wolfbauer, Gertrud; Cheung, Marian C et al. (2015) Inhibition of thrombin generation in human plasma by phospholipid transfer protein. Thromb J 13:24
Rosenthal, Elisabeth; Blue, Elizabeth; Jarvik, Gail P (2015) Next-generation gene discovery for variants of large impact on lipid traits. Curr Opin Lipidol 26:114-9
Shao, Baohai; Tang, Chongren; Sinha, Abhishek et al. (2014) Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res 114:1733-42
Wight, Thomas N; Kinsella, Michael G; Evanko, Stephen P et al. (2014) Versican and the regulation of cell phenotype in disease. Biochim Biophys Acta 1840:2441-51
Zambon, Alberto; Zhao, Xue-Qiao; Brown, B Greg et al. (2014) Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 113:1494-8
Phan, Binh An P; Moore, Andrew B; Davis, Joseph et al. (2014) Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J Clin Lipidol 8:489-93
Vuletic, Simona; Kennedy, Hal; Albers, John J et al. (2014) Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. Mult Scler Relat Disord 3:533-541

Showing the most recent 10 out of 485 publications